Related Experiment Video

Updated: Feb 18, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

S L Villegas1, S Darb-Esfahani1,2, G von Minckwitz3

  • 1Institute of Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Breast Cancer Research and Treatment
|November 28, 2017
PubMed
Abstract

Insights

Cyclin D1 is overexpressed in some hormone receptor-positive breast cancers after neoadjuvant chemotherapy. While not prognostic for disease-free survival, this marker can help stratify tumors for targeted post-chemotherapy treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Hormone receptor (HR)-positive breast cancer (BC) often responds poorly to neoadjuvant chemotherapy (NACT).
  • The Cyclin D1-CDK4/CDK6 complex represents a potential therapeutic target for adjuvant or post-neoadjuvant treatment strategies.
  • Identifying patients with Cyclin D1 overexpression in residual tumors could guide personalized treatment decisions.

Purpose of the Study:

  • To determine Cyclin D1 expression levels in residual breast cancer tissue following NACT.
  • To correlate Cyclin D1 expression with clinicopathological parameters in breast cancer patients.
  • To evaluate the prognostic value of Cyclin D1 expression for disease-free survival (DFS) after NACT.

Main Methods:

  • Retrospective analysis of nuclear Cyclin D1 expression using tissue microarrays from 284 patients in the GeparTrio and GeparQuattro neoadjuvant trials.
  • Standardized immunoreactive score (IRS) was used for evaluation after defining a cut-off value.

Main Results:

  • High Cyclin D1 expression (IRS ≥ 6) was detected in 37.3% of specimens.
  • Increased Cyclin D1 expression was significantly associated with HR-positive tumors (p=0.02).
  • Low Cyclin D1 levels correlated with early clinical tumor stages (1-3) (p=0.03).

Conclusions:

  • Measurable nuclear Cyclin D1 expression exists in post-NACT residual tumor tissue of HR-positive breast cancer.
  • Cyclin D1 expression was not found to be prognostic for DFS after NACT in this cohort.
  • The study defined a cut-off for Cyclin D1 expression, enabling tumor stratification for potential targeted therapies, with ongoing prospective evaluation in the Penelope-B trial.
Keywords:
Breast cancerCyclin D-CDK4/CDK6Cyclin D1Cyclin D1 TMACyclin D1 overexpressionNeoadjuvant chemotherapyPrognose Cyclin D1

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.6K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K